ESPERION Appoints Sheldon Koenig as President and CEO
May 17 2021 - 9:01AM
ESPERION (NASDAQ: ESPR), today announced the appointment of Sheldon
Koenig as president and chief executive officer and board member,
effective immediately. With over 30 years of commercial and
operational experience as an accomplished leader in the
cardiovascular space, Mr. Koenig has served as the company’s chief
operating officer since December 2020. He is succeeding Tim
Mayleben, who after serving in this role for the last decade, has
decided to step down and will continue to serve as a senior advisor
to help ensure a smooth transition.
“As ESPERION enters this critical growth phase, Sheldon’s
extensive commercial leadership and product launch experience will
be invaluable,” said Nicole Vitullo, lead independent director for
ESPERION. “On behalf of the board, we want to recognize Tim’s
contributions over the last decade as he led the team’s successful
development and approval of two new cholesterol lowering medicines,
NEXLETOL® and NEXLIZET® in the U.S. and Europe and established
strong partnerships outside of the U.S.. We appreciate Tim’s years
of service and wish him the best in the future.”
“I believe strongly in the promise of our medicines and the role
they can play in managing lipids and cardiovascular disease for
patients,” said Mr. Koenig. “With two products recently launched in
the U.S. and Europe, our U.S. commercial structure in place,
leading partners and passionate colleagues, ESPERION is positioned
for success in our mission of Lipid Management for Everyone. I am
thrilled to work with this team and lead this exciting period of
growth for our company.”
Mr. Mayleben added, “Sheldon has distinguished himself
throughout his career as an accomplished leader in the
commercialization of first in class products and he has
particularly deep expertise in cardiovascular disease medicines.
Since joining ESPERION in December, he has shown exceptional
leadership across almost all facets of the company. I believe this
is an appropriate time for this leadership transition and I look
forward to supporting Sheldon in his new role.”
Previously, Mr. Koenig was chief commercial officer at Portola
Pharmaceuticals until the company was acquired by Alexion
Pharmaceuticals. At Portola, he built the U.S. commercial and
operations functions as well as the global organization. Earlier,
Mr. Koenig was senior vice president and head of the cardiovascular
franchise for Sanofi, where he led U.S. business operations and
product launches in more than 20 countries. Mr. Koenig began his
career at Merck, where he served for more than 25 years in roles of
increasing responsibility within the company’s cardiovascular
thrombosis franchises. At Merck, he served as vice president and
global brand leader for the cardiovascular division. He led
marketing for Zetia, at the time the leading non-statin cholesterol
lowering medicine, franchise. He holds an MBA from Monmouth
University and a B.S. from Drexel University, and completed the
leadership program at The Wharton School.
ESPERION Therapeutics
ESPERION is The Lipid Management Company. Our goal is lipid
management for everybody, that’s why we work hard to make our
medicines easy to get, easy to take and easy to have. We discover,
develop and commercialize innovative medicines and combinations to
lower cholesterol, especially for patients whose needs aren’t being
met by the status quo. Our entrepreneurial team of industry leaders
is inclusive, passionate and resourceful. We are singularly focused
on managing cholesterol so you can improve your health easily.
ESPERION commercializes NEXLETOL® (bempedoic acid) and NEXLIZET®
(bempedoic acid and ezetimibe) Tablets and is the leader in the
development of convenient oral, once-daily non-statin
LDL-cholesterol lowering drugs for patients with high levels of bad
cholesterol. For more information, please visit www.esperion.com
and follow us on Twitter at www.twitter.com/EsperionInc.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding commercialization
plans. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties that could cause ESPERION's actual results
to differ significantly from those projected, including, without
limitation, the impact of COVID-19 on our business, clinical
activities, supply chain, commercial development and launch plans,
and the risks detailed in ESPERION's filings with the Securities
and Exchange Commission. Any forward-looking statements contained
in this press release speak only as of the date hereof, and
ESPERION disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
Contact:Ben
Churchbchurch@esperion.com 734-864-6774
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024